Exploring Anticancer and Antituberculosis Activities of Pt(II) Quinazoline Complexes Derived from EMNEDAQZHO ((E)-2-methyl-3-(1-(naphthalen-1-yl)ethylideneamino)quinazolin-4(3H)-one): Insights and Applications

In vitro cytotoxicity assessment has become a critical aspect of developing therapeutic agents for a wide array of human diseases, including cancer, autoimmune disorders, and infectious ailments like tuberculosis (TB). Metal complexes, especially those based on platinum, have garnered substantial attention in cancer treatment due to their notable efficacy, typified by cisplatin's ability to induce filamentous growth. Cisplatin, an inorganic heavy metal complex, shares mechanistic similarities with certain cell-cycle-phase non-specific alkylating agents, functioning via the formation of interstrand DNA cross-links and DNA adducts, thereby impeding DNA, RNA, and protein synthesis, primarily in cancer cells. TB remains a significant global health challenge, necessitating the development of novel vaccines and drugs to combat its spread. The rational development of antitubercular agents hinges on a comprehensive understanding of the genetics, physiology, and host interactions of Mycobacterium tuberculosis. In this study, platinum metal complexes derived from (E)-2-methyl-3-(1-(naphthalen-1-yl)ethylidene amino) quinazolin-4(3H)-one [EMNEDAQZHO] were synthesized and evaluated for their potential as anticancer and antituberculosis agents. Meticulous molecule selection, protein data bank (PDB) optimization, and multi-component reaction methods were employed for synthesis. Characterization of the resultant complexes was conducted using various analytical techniques, encompassing IR, TLC, NMR, XRD, TGA, Mass spectrum, and physicochemical parameter analysis. The prioritized molecules underwent in vitro assays to assess their anticancer activity via the MTT assay and antituberculosis activity using M. tuberculosis strain MTCC 300 as standards. The findings reveal promising potential for platinum metal complexes derived from quinazolinone Schiff bases [EMNEDAQZHO] as both anticancer and antituberculosis agents, as evidenced by their observed inhibitory effects in in vitro cytotoxicity assays and evaluations against M. tuberculosis strain MTCC 300. This study underscores the therapeutic promise of these novel platinum metal complexes and emphasizes the necessity for further investigations to elucidate their mechanisms of action and therapeutic efficacy in both preclinical and clinical contexts.